ATE300952T1 - Verfahren zur verabreichung von wirkstoffen in das zentrale nervensystem oder lymphsystem - Google Patents
Verfahren zur verabreichung von wirkstoffen in das zentrale nervensystem oder lymphsystemInfo
- Publication number
- ATE300952T1 ATE300952T1 AT00984018T AT00984018T ATE300952T1 AT E300952 T1 ATE300952 T1 AT E300952T1 AT 00984018 T AT00984018 T AT 00984018T AT 00984018 T AT00984018 T AT 00984018T AT E300952 T1 ATE300952 T1 AT E300952T1
- Authority
- AT
- Austria
- Prior art keywords
- central nervous
- nervous system
- administration
- active ingredients
- disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20070899P | 1999-12-09 | 1999-12-09 | |
PCT/US2000/033220 WO2001041782A2 (en) | 1999-12-09 | 2000-12-08 | Method for administering a cytokine to the central nervous system and the lymphatic system |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE300952T1 true ATE300952T1 (de) | 2005-08-15 |
Family
ID=22742853
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT00984018T ATE300952T1 (de) | 1999-12-09 | 2000-12-08 | Verfahren zur verabreichung von wirkstoffen in das zentrale nervensystem oder lymphsystem |
Country Status (10)
Country | Link |
---|---|
US (3) | US20010043915A1 (de) |
EP (1) | EP1237567B1 (de) |
JP (1) | JP2003516360A (de) |
AT (1) | ATE300952T1 (de) |
AU (1) | AU783208B2 (de) |
CA (1) | CA2393688A1 (de) |
DE (1) | DE60021760T2 (de) |
IL (1) | IL150109A0 (de) |
NO (1) | NO20022731L (de) |
WO (1) | WO2001041782A2 (de) |
Families Citing this family (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060024270A1 (en) * | 2000-08-23 | 2006-02-02 | The New York Hospital Medical Center Of Queens | Compositions and methods for preventing or treating encephalitis with interferon |
US6589591B1 (en) * | 2001-07-10 | 2003-07-08 | Baylor College Of Medicine | Method for treating medical devices using glycerol and an antimicrobial agent |
AU2002367394A1 (en) * | 2001-12-28 | 2003-07-24 | Genzyme Corporation | Bioresorbable foam packing device and use thereof |
AU2003209755B2 (en) * | 2002-02-06 | 2007-11-22 | Ares Trading S.A. | Tumor necrosis factor combined with interferon in demyelinating diseases |
US20030229025A1 (en) * | 2002-02-25 | 2003-12-11 | Chiron Corporation | Intranasal administration of MC4-R agonists |
US20040037809A1 (en) * | 2002-06-28 | 2004-02-26 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of interferon beta |
WO2004022593A2 (en) * | 2002-09-09 | 2004-03-18 | Nautilus Biotech | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules |
WO2004078943A2 (en) | 2003-03-04 | 2004-09-16 | California Institute Of Technology | Alternative heterocycles for dna recognition |
AU2004222529A1 (en) * | 2003-03-19 | 2004-09-30 | Ares Trading S.A. | INF-beta alone or in combination with other medicaments for treating Alzheimer's disease and demens disorders |
FR2864901B1 (fr) * | 2004-01-09 | 2007-10-05 | Philippe Perovitch | Composition pour le traitement au contact des hyposialies, incluant de la pilocarpine et a effets multiples |
WO2005071101A1 (en) * | 2004-01-23 | 2005-08-04 | University Hospital Of Basel | Treatment of hepatitis c infection by increasing stat1 methylation |
KR20070030264A (ko) * | 2004-06-07 | 2007-03-15 | 나스텍 파마수티컬 컴퍼니 인코포레이티드 | 단백질 또는 폴리펩티드 안정제 성분을 함유하지 않은인터페론 베타의 비강내 투여를 위한 제형들 |
US9216161B2 (en) | 2004-08-13 | 2015-12-22 | Healthpartners Research Foundation | Methods of treating Huntington's disease comprising administering metal chelators to the upper one-third of the nasal cavity |
US7618615B2 (en) | 2004-08-13 | 2009-11-17 | Healthpartners Research Foundation | Methods for providing neuroprotection for the animal central nervous system against neurodegeneration caused by ischemia |
US7776312B2 (en) * | 2004-08-13 | 2010-08-17 | Healthpartners Research Foundation | Method of treating Alzheimer's disease comprising administering deferoxamine (DFO) to the upper one-third of the nasal cavity |
US20060046962A1 (en) | 2004-08-25 | 2006-03-02 | Aegis Therapeutics Llc | Absorption enhancers for drug administration |
US20140162965A1 (en) | 2004-08-25 | 2014-06-12 | Aegis Therapeutics, Inc. | Compositions for oral drug administration |
US20090047347A1 (en) * | 2005-07-29 | 2009-02-19 | Aegis Therapeutics, Inc. | Compositions for Drug Administration |
US9114069B2 (en) * | 2004-08-25 | 2015-08-25 | Aegis Therapeutics, Llc | Antibacterial compositions for drug administration |
US9895444B2 (en) | 2004-08-25 | 2018-02-20 | Aegis Therapeutics, Llc | Compositions for drug administration |
US8268791B2 (en) * | 2004-08-25 | 2012-09-18 | Aegis Therapeutics, Llc. | Alkylglycoside compositions for drug administration |
US20060046969A1 (en) * | 2004-08-25 | 2006-03-02 | Aegis Therapeutics Llc | Antibacterial compositions for drug administration |
US8642564B2 (en) * | 2004-08-25 | 2014-02-04 | Aegis Therapeutics, Llc | Compositions for drug administration |
EP1877434A2 (de) * | 2005-05-04 | 2008-01-16 | Nautilus Biotech | Modifizierte interferon-gamma-polypeptide und verfahren zur anwendung modifizierter interferon-gamma-polypeptide |
US20090317377A1 (en) | 2005-08-26 | 2009-12-24 | Yeomans David C | Therapy procedure for drug delivery for trigeminal pain |
WO2007110231A2 (en) * | 2006-03-28 | 2007-10-04 | Nautilus Biotech, S.A. | MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES |
US7534595B2 (en) * | 2006-06-12 | 2009-05-19 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
US8226949B2 (en) | 2006-06-23 | 2012-07-24 | Aegis Therapeutics Llc | Stabilizing alkylglycoside compositions and methods thereof |
EP1915986A1 (de) * | 2006-10-23 | 2008-04-30 | BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH | Wachstumsfaktorhaltige Lipidformulierungen |
CA2687505C (en) | 2007-06-08 | 2013-10-08 | Healthpartners Research Foundation | Pharmaceutical compositions and methods for enhancing targeting of therapeutic compounds to the central nervous system |
US9707274B2 (en) | 2007-06-08 | 2017-07-18 | Healthpartners Research & Education | Methods for preventing and treating post-traumatic stress disorder (PTSD) |
US8221358B2 (en) * | 2007-11-20 | 2012-07-17 | Warsaw Orthopedic, Inc. | Devices and methods for delivering drug depots to a site beneath the skin |
ES2586032T3 (es) | 2008-03-28 | 2016-10-11 | Hale Biopharma Ventures, Llc | Administración de composiciones de benzodiazepinas |
US9650639B2 (en) | 2008-05-19 | 2017-05-16 | Advaxis, Inc. | Dual delivery system for heterologous antigens |
US9017660B2 (en) | 2009-11-11 | 2015-04-28 | Advaxis, Inc. | Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors |
ES2741730T3 (es) | 2008-05-19 | 2020-02-12 | Advaxis Inc | Sistema de administración doble para antígenos heterólogos que comprende una cepa de Listeria recombinante atenuada por la mutación de dal/dat y la deleción de ActA que comprende una molécula de ácido nucleico que codifica una proteína de fusión de listeriolisina O - antígeno prostático específico |
US8129499B2 (en) | 2008-06-13 | 2012-03-06 | Wisconsin Alumni Research Foundation | Antiviral peptides against influenza virus |
WO2009152518A1 (en) | 2008-06-13 | 2009-12-17 | Wisconsin Alumni Research Foundation | Novel peptide adjuvant for influenza vaccination |
US20100106136A1 (en) * | 2008-10-29 | 2010-04-29 | Warsaw Orthopedic, Inc. | Drug delivery device with sliding cartridge |
US20100106132A1 (en) * | 2008-10-29 | 2010-04-29 | Warsaw Orthopedic, Inc. | Drug cartridge for delivering a drug depot comprising superior and inferior covers |
US9352137B2 (en) * | 2008-10-29 | 2016-05-31 | Warsaw Orthopedic, Inc. | Drug cartridge for delivering a drug depot comprising a bulking agent and/or cover |
EP2375895A4 (de) * | 2008-12-11 | 2012-05-30 | Merck Sharp & Dohme | Verfahren zur behandlung von morbus alzheimer und damit verwandten leiden |
US8440631B2 (en) | 2008-12-22 | 2013-05-14 | Aegis Therapeutics, Llc | Compositions for drug administration |
ES2784189T3 (es) | 2009-03-27 | 2020-09-23 | Academia Sinica | Métodos y composiciones para la inmunización contra virus |
US20120189581A1 (en) | 2009-07-24 | 2012-07-26 | Schultz-Cherry Stacey L | Use of toxoplasma and derived compositions to prevent or treat microbial infections |
US10016617B2 (en) | 2009-11-11 | 2018-07-10 | The Trustees Of The University Of Pennsylvania | Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers |
GB0921525D0 (en) * | 2009-12-08 | 2010-01-27 | Isis Innovation | Product and method |
US9468662B2 (en) | 2010-07-12 | 2016-10-18 | Orphit | Use of the PAT nonapeptide in the treatment and prevention of neurodegenerative diseases |
FR2962335B1 (fr) * | 2010-07-12 | 2013-01-18 | Cll Pharma | Utilisation du nonapeptide pat dans le traitement et la prevention des maladies neurodegeneratives |
EP2621527A4 (de) | 2010-10-01 | 2015-12-09 | Univ Pennsylvania | Verwendung von listerien-impfstoffvektoren zur umkehrung einer impfstoff-unempfänglichkeit bei patienten mit parasiteninfektionen |
BR112013022249B8 (pt) | 2011-03-03 | 2022-10-25 | Impel Neuropharma Inc | Dispositivo de distribuição de droga nasal |
EP2683400A4 (de) | 2011-03-11 | 2014-09-17 | Advaxis | Adjuvanzien auf listerien-basis |
CN103619485B (zh) | 2011-05-09 | 2017-08-08 | 英倍尔药业股份有限公司 | 用于鼻腔药物递送的喷嘴 |
US8609088B2 (en) | 2011-05-10 | 2013-12-17 | Regents Of The University Of Minnesota | Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases |
WO2012174158A2 (en) | 2011-06-14 | 2012-12-20 | Hale Biopharma Ventures, Llc | Administration of benzodiazepine |
US8987199B2 (en) | 2011-06-15 | 2015-03-24 | Nerve Access, Inc. | Pharmaceutical compositions for intranasal administration for the treatment of neurodegenerative disorders |
US9486540B2 (en) | 2012-03-09 | 2016-11-08 | Northeastern University | Methods for delivery to the central nervous system of nucleic acid nanoparticles to treat central nervous system disorders |
SG10201700392UA (en) | 2012-03-12 | 2017-03-30 | Advaxis Inc | Suppressor cell function inhibition following listeria vaccine treatment |
US9033912B2 (en) | 2012-03-28 | 2015-05-19 | Warsaw Orthopedic, Inc. | Drug delivery system |
US20130280297A1 (en) | 2012-04-11 | 2013-10-24 | Lori Neal | Use of toxoplasma gene products to prevent or treat microbial infections |
US10279012B2 (en) | 2013-03-11 | 2019-05-07 | Healthpartners Research & Education | Methods of treating and preventing social communication disorder in patients by intranasal administration of insulin |
WO2014179228A1 (en) | 2013-04-28 | 2014-11-06 | Impel Neuropharma Inc. | Medical unit dose container |
SG11201509419QA (en) | 2013-05-15 | 2015-12-30 | Univ Minnesota | Adeno-associated virus mediated gene transfer to the central nervous system |
US9901684B2 (en) | 2013-10-17 | 2018-02-27 | Warsaw Orthopedic, Inc. | Drug delivery device with retaining member |
US10314911B2 (en) | 2014-04-08 | 2019-06-11 | Healthpartners Research & Education | Methods for protecting and treating traumatic brain injury, concussion and brain inflammation with intranasal insulin |
WO2015179415A1 (en) | 2014-05-19 | 2015-11-26 | Novartis Ag | Methods of treating anorexia |
US9775978B2 (en) | 2014-07-25 | 2017-10-03 | Warsaw Orthopedic, Inc. | Drug delivery device and methods having a retaining member |
USD809652S1 (en) | 2014-07-25 | 2018-02-06 | Warsaw Orthopedic, Inc. | Drug delivery device |
US10080877B2 (en) | 2014-07-25 | 2018-09-25 | Warsaw Orthopedic, Inc. | Drug delivery device and methods having a drug cartridge |
EP4331670A3 (de) | 2015-01-07 | 2024-05-29 | Tonix Pharma Limited | Magnesiumhaltige oxytocinformulierungen und verfahren zur verwendung |
MA41644A (fr) | 2015-03-03 | 2018-01-09 | Advaxis Inc | Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation |
US10335435B2 (en) | 2015-05-22 | 2019-07-02 | Marco Merida | Method for endoscopically delivering stem cells to the brain using an intranasal, injectable approach |
US10076650B2 (en) | 2015-11-23 | 2018-09-18 | Warsaw Orthopedic, Inc. | Enhanced stylet for drug depot injector |
IL262211B2 (en) | 2016-04-15 | 2024-01-01 | Univ Pennsylvania | Gene therapy for the treatment of type II mucositis |
USD802757S1 (en) | 2016-06-23 | 2017-11-14 | Warsaw Orthopedic, Inc. | Drug pellet cartridge |
US10434261B2 (en) | 2016-11-08 | 2019-10-08 | Warsaw Orthopedic, Inc. | Drug pellet delivery system and method |
CN106620656A (zh) * | 2017-03-03 | 2017-05-10 | 上海唯科生物制药有限公司 | 一种肿瘤坏死因子舌下给药制剂及其制备方法 |
WO2019060115A1 (en) | 2017-09-19 | 2019-03-28 | Advaxis, Inc. | COMPOSITIONS AND METHODS FOR LYOPHILIZATION OF BACTERIA OR LISTERIA STRAINS |
KR20200104852A (ko) | 2017-09-22 | 2020-09-04 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Ii형 점액다당류증의 치료를 위한 유전자 요법 |
WO2019157099A1 (en) | 2018-02-06 | 2019-08-15 | Aegis Therapeutics, Llc | Intranasal epinephrine formulations and methods for the treatment of disease |
WO2019241579A1 (en) | 2018-06-13 | 2019-12-19 | Wisconsin Alumni Research Foundation | Toxoplasma gondii vaccine |
KR20210109007A (ko) | 2019-01-03 | 2021-09-03 | 임펠 뉴로파마 인코포레이티드 | 비강 약물 전달 장치 |
AU2021297245A1 (en) | 2020-06-23 | 2023-02-02 | Illumina Software, Inc. | Methods for diagnosing respiratory pathogens and predicting covid-19 related outcomes |
EP4319803A1 (de) | 2021-04-08 | 2024-02-14 | Vaxthera SAS | Coronavirus-impfstoff, der ein mosaikprotein enthält |
KR20240132250A (ko) | 2021-10-19 | 2024-09-03 | 오라제닉스, 인코포레이티드 | 뇌진탕을 포함한 외상성 뇌 손상(tbi)의 치료를 위한 호흡 구동식 비강 디바이스 및 방법 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4462985A (en) | 1980-08-22 | 1984-07-31 | University Of Illinois Foundation | Delivery of biologically active components of heterologous species interferon isolates |
US4479932A (en) * | 1982-05-18 | 1984-10-30 | University Of Florida | Brain-specific drug delivery |
US5910304A (en) | 1982-12-13 | 1999-06-08 | Texas A&M University System | Low-dose oral administration of interferons |
US4820515A (en) | 1982-12-13 | 1989-04-11 | Texas A&M University System | Method of using interferon in low dosage to regulate appetite and efficiency of food utilization |
US4497795A (en) | 1982-12-13 | 1985-02-05 | The Texas A&M University System | Method of regulating appetite and efficiency of food utilization employing interferon |
SU1139444A1 (ru) | 1982-12-15 | 1985-02-15 | Iretskij Andrej N | Способ введени нейротропных и гормональных препаратов |
US4746508A (en) * | 1983-06-06 | 1988-05-24 | Beth Israel Hospital Assn. | Drug administration |
US4857316A (en) * | 1984-10-03 | 1989-08-15 | Syntex (U.S.A.) Inc. | Synergistic antiviral composition |
IL76591A0 (en) * | 1984-10-05 | 1986-02-28 | Bioferon Biochem Substanz | Pharmaceutical compositions containing ifn-ypsilon and processes for the preparation thereof |
US4959314A (en) * | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
US4820514A (en) | 1985-12-30 | 1989-04-11 | Texas A&M University System | Low dosage of interferon to enhance vaccine efficiency |
US6024983A (en) * | 1986-10-24 | 2000-02-15 | Southern Research Institute | Composition for delivering bioactive agents for immune response and its preparation |
CA1320905C (en) | 1986-11-06 | 1993-08-03 | Joseph M. Cummins | Treatment of immuno-resistant disease |
ZA878295B (en) | 1986-11-06 | 1988-05-03 | Amarillo Cell Culture Co. Inc. | Treatment of immuno-resistant disease |
US5017371A (en) | 1988-01-06 | 1991-05-21 | Amarillo Cell Culture Company, Incorporated | Method for reducing side effects of cancer therapy |
US5906816A (en) * | 1995-03-16 | 1999-05-25 | University Of Florida | Method for treatment of autoimmune diseases |
GB8918264D0 (en) * | 1989-08-10 | 1989-09-20 | Furnell David | Rotary display unit |
US5624898A (en) * | 1989-12-05 | 1997-04-29 | Ramsey Foundation | Method for administering neurologic agents to the brain |
AU6909091A (en) | 1989-12-05 | 1991-06-26 | Ramsey Foundation | Neurologic agents for nasal administration to the brain |
US5215741A (en) | 1990-10-30 | 1993-06-01 | Amarillo Cell Culture Company, Incorporated | Method for prevention of parasite infections |
US5676942A (en) | 1992-02-10 | 1997-10-14 | Interferon Sciences, Inc. | Composition containing human alpha interferon species proteins and method for use thereof |
EP0566135A1 (de) * | 1992-04-17 | 1993-10-20 | Takeda Chemical Industries, Ltd. | Transmucosale Zubereitungen enthaltend ein Peptid und ein Cytidinderivat |
AU672617B2 (en) * | 1992-06-22 | 1996-10-10 | Regents Of The University Of California, The | Glycine receptor antagonists and the use thereof |
JPH0741428A (ja) | 1993-07-30 | 1995-02-10 | Teijin Ltd | ペプチド、蛋白質性薬物経鼻・経肺製剤 |
US5514670A (en) * | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
US5545723A (en) * | 1994-03-15 | 1996-08-13 | Biogen Inc. | Muteins of IFN-β |
US5675942A (en) * | 1995-08-28 | 1997-10-14 | Crawford; Van | Wall panel alignment device and spacer |
BR9709068A (pt) * | 1996-05-09 | 2000-01-11 | Pharma Pacific Pty Ltd | Processo de tratamento. |
HUP9602024A3 (en) * | 1996-07-25 | 1999-05-28 | Toth Sandor | Pharmaceutical composition containing aminoacid for external use |
US6036949A (en) | 1998-03-05 | 2000-03-14 | Amarillo Biosciences, Inc. | Treatment of fibromyalgia with low doses of interferon |
WO2000033814A2 (en) * | 1998-12-09 | 2000-06-15 | Chiron Corporation | Method for administering agents to the central nervous system |
EP1031347B1 (de) | 1999-01-27 | 2002-04-17 | Idea Ag | Transnasaler Transport bzw. Impfung mit hochadaptierbaren Trägern |
-
2000
- 2000-12-08 AU AU20698/01A patent/AU783208B2/en not_active Ceased
- 2000-12-08 US US09/733,168 patent/US20010043915A1/en not_active Abandoned
- 2000-12-08 JP JP2001543126A patent/JP2003516360A/ja active Pending
- 2000-12-08 DE DE60021760T patent/DE60021760T2/de not_active Expired - Fee Related
- 2000-12-08 CA CA002393688A patent/CA2393688A1/en not_active Abandoned
- 2000-12-08 IL IL15010900A patent/IL150109A0/xx unknown
- 2000-12-08 WO PCT/US2000/033220 patent/WO2001041782A2/en active IP Right Grant
- 2000-12-08 EP EP00984018A patent/EP1237567B1/de not_active Expired - Lifetime
- 2000-12-08 AT AT00984018T patent/ATE300952T1/de not_active IP Right Cessation
-
2002
- 2002-03-20 US US10/102,163 patent/US6991785B2/en not_active Expired - Fee Related
- 2002-06-07 NO NO20022731A patent/NO20022731L/no not_active Application Discontinuation
-
2005
- 2005-09-09 US US11/222,669 patent/US20060159626A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
IL150109A0 (en) | 2002-12-01 |
NO20022731D0 (no) | 2002-06-07 |
US20020141971A1 (en) | 2002-10-03 |
EP1237567B1 (de) | 2005-08-03 |
NO20022731L (no) | 2002-08-08 |
US20060159626A1 (en) | 2006-07-20 |
WO2001041782A2 (en) | 2001-06-14 |
WO2001041782A3 (en) | 2002-01-17 |
AU2069801A (en) | 2001-06-18 |
CA2393688A1 (en) | 2001-06-14 |
EP1237567A2 (de) | 2002-09-11 |
DE60021760T2 (de) | 2006-06-08 |
DE60021760D1 (de) | 2005-09-08 |
AU783208B2 (en) | 2005-10-06 |
JP2003516360A (ja) | 2003-05-13 |
US6991785B2 (en) | 2006-01-31 |
US20010043915A1 (en) | 2001-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE300952T1 (de) | Verfahren zur verabreichung von wirkstoffen in das zentrale nervensystem oder lymphsystem | |
WO2005000215A3 (en) | Methods for treating pain | |
DE69333321D1 (de) | Verwendung eines Consensus-Interferons zur Reduzierung der Nebeneffekte in der Interferon Behandlung von viralen Hepatiten. | |
JP2003516360A5 (de) | ||
CY1107995T1 (el) | ΑΝΑΣΤΟΛΗ ΔΡΑΣΤΙΚΟΤΗΤΑΣ p38 ΚΙΝΑΣΗΣ ΧΡΗΣΙΜΟΠΟΙΩΝΤΑΣ ΑΡΥΛ ΚΑΙ ΕΤEPΟΑΡΥΛ ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ ΕΤEPΟΚΥΚΛΙΚΕΣ ΟΥΡΙΕΣ | |
PT858343E (pt) | Terapia por infusao continua de uma dose baixa de citoquina | |
BR9814458A (pt) | Composto, composição farmacêutica e método de tratamento de disfunções afetivas | |
FI852626A0 (fi) | Menetelmä ihmisen tuumorinekroositekijän valmistamiseksi ja sitä koodaava DNA | |
DE69928563D1 (de) | Verabreichung von neurotropischen wirkstoffen in das zentrale nervensystem | |
RU98115594A (ru) | Модуляция экспрессии тн1/тн2 цитокинов рибавирином и аналогами рибавирина в активированных т-лимфоцитах | |
AU2173400A (en) | Method for administering agents to the central nervous system | |
DE60237721D1 (de) | Kombinationstherapie mit omega-interferon zur behandlung von hepatitis c virus oder gelbfieber virus infektionen | |
ATE65403T1 (de) | Pharmazeutischer stoff fuer die foerderung der wiederherstellung der haematopoietischen faehigkeit. | |
ATE71662T1 (de) | Einen menschlichen granulozytkoloniereizfaktor fuer die behandlung von leukopenien enthaltende pharmazeutische zubereitung. | |
EP0231819A3 (en) | Pharmaceutical agent for the treatment of myelogenous leukemia | |
ATE320270T1 (de) | Zusammensetzungen und methoden zur zielgerichteten abgabe von biologisch aktivenfaktoren | |
Naveau et al. | Interleukin-1 receptor antagonist plasma concentration is specifically increased by alpha-2A-interferon treatment | |
DE60235955D1 (de) | Zusammensetzungen und verfahren zur erhöhung der zytokin-aktivität und zur behandlung der hypotension assoziiert mit der verabreichung von zytokinen | |
ATE257727T1 (de) | Zusammensetzung und system zur iontophoretischen transdermalen abgabe von medikamenten | |
ATE80998T1 (de) | Verwendung von nalmefen zur herstellung eines arzneimittels zur behandlung der schaedigung des zentralnervensystems. | |
DE60023944D1 (de) | Replikationsunfähige herpesvirus-vektoren | |
KR900701311A (ko) | 재조합 사람 α-인터페론을 병소내로 투여하여 편평세포 암을 치료하는 방법 | |
SU1187830A1 (ru) | Способ лечени вирусного гепатита у детей | |
Gutmann et al. | Origin of intramuscular nerve action potential. | |
Seki et al. | Induction of eosinophil chemotactic factor production from human peripheral blood mononuclear cells by solubilized BALL-1, a B cell lymphoma line |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |